Literature DB >> 30409826

GPCR structure and function relationship: identification of a biased apelin receptor mutant.

Ting Ban1, Xun Li1, Xiaochuan Ma1, Hui Yang1, Yunpeng Song1, Yaping Sun1, Michelle Shen2, Na Li1, Mei-Yun Zhang1, Yingli Ma1, Wenge Zhong1, Mingqiang Zhang1, Liaoyuan A Hu3.   

Abstract

Biased ligands of G protein-coupled receptors (GPCRs) may have improved therapeutic benefits and safety profiles. However, the molecular mechanism of GPCR biased signaling remains largely unknown. Using apelin receptor (APJ) as a model, we systematically investigated the potential effects of amino acid residues around the orthosteric binding site on biased signaling. We discovered that a single residue mutation I109A (I1093.32) in the transmembrane domain 3 (TM3) located in the deep ligand-binding pocket was sufficient to convert a balanced APJ into a G protein signaling biased receptor. APJ I109A mutant receptor retained full capabilities in ligand binding and G protein activation, but was defective in GRK recruitment, β-arrestin recruitment, and downstream receptor-mediated ERK activation. Based on molecular dynamics simulations, we proposed a molecular mechanism for biased signaling of I109A mutant receptor. We postulate that due to the extra space created by I109A mutation, the phenyl group of the last residue (Phe-13) of apelin rotates down and initiates a cascade of conformational changes in TM3. Phe-13 formed a new cluster of hydrophobic interactions with the sidechains of residues in TM3, including F1103.33 and M1133.36, which stabilizes the mutant receptor in a conformation favoring biased signaling. Interruption of these stabilizing interactions by double mutation F110A/I109A or M113A/I109A largely restored the β-arrestin-mediated signaling. Taken together, we describe herein the discovery of a biased APJ mutant receptor and provide detailed molecular insights into APJ signaling selectivity, facilitating the discovery of novel therapeutics targeting APJ.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  G protein-coupled receptors; apelin receptor; molecular dynamics; pharmacology; signaling bias

Mesh:

Substances:

Year:  2018        PMID: 30409826     DOI: 10.1042/BCJ20180740

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  5 in total

Review 1.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

2.  Ligand-Directed GPCR Antibody Discovery.

Authors:  Qi Zhao; Amanda Chapman; Yan Huang; Mary Ferguson; Shannon McBride; Meghan Kelly; Michael Weiner; Xiaofeng Li
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases.

Authors:  Li-Kun Yang; Zhi-Shuai Hou; Ya-Xiong Tao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-17       Impact factor: 5.187

4.  A network map of apelin-mediated signaling.

Authors:  Shobha Dagamajalu; D A B Rex; Pushparani Devi Philem; Jan K Rainey; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-04-02       Impact factor: 5.782

5.  Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors.

Authors:  Huanhuan Ren; Jian Li; Ning Zhang; Liaoyuan A Hu; Yingli Ma; Philip Tagari; Jianqing Xu; Mei-Yun Zhang
Journal:  Commun Biol       Date:  2020-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.